Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Michael Wang, Luis Fayad, Fernando Cabanillas, Fredrick Hagemeister, Peter McLaughlin, Maria A. Rodriguez, Larry W. Kwak, Yuhong Zhou, Hagop Kantarjian, Jorge Romaguera

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences